OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)